EXTENSIVE MACULAR ATROPHY WITH PSEUDODRUSEN (EMAP)
Clinical trials for EXTENSIVE MACULAR ATROPHY WITH PSEUDODRUSEN (EMAP) explained in plain language.
Never miss a new study
Get alerted when new EXTENSIVE MACULAR ATROPHY WITH PSEUDODRUSEN (EMAP) trials appear
Sign up with your email to follow new studies for EXTENSIVE MACULAR ATROPHY WITH PSEUDODRUSEN (EMAP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Eye injection trial aims to slow vision loss in retinal diseases
Disease control OngoingThis small, early-stage study is testing whether injections of an anti-inflammatory drug (adalimumab) into the eye can help preserve vision in people with inherited retinal diseases like retinitis pigmentosa (RP). Thirty participants will receive three injections over four months…
Matched conditions: EXTENSIVE MACULAR ATROPHY WITH PSEUDODRUSEN (EMAP)
Phase: PHASE1, PHASE2 • Sponsor: Centro de Pesquisa Rubens Siqueira • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
Could your own blood help save your sight? experimental eye treatment shows promise
Disease control OngoingThis small pilot study is testing whether injections of a patient's own concentrated platelets (platelet-rich plasma) around the eye can help slow vision loss in two serious retinal diseases: retinitis pigmentosa and extensive macular atrophy. Thirty participants will receive thr…
Matched conditions: EXTENSIVE MACULAR ATROPHY WITH PSEUDODRUSEN (EMAP)
Phase: PHASE1, PHASE2 • Sponsor: Rubens Camargo Siqueira • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC